Crispr Therapeutics AG vs Remitly Global Inc — how do they compare? Crispr Therapeutics AG trades at $54.08 (market cap $5.23B), while Remitly Global Inc trades at $23.73 (market cap $4.97B). The key difference: Crispr Therapeutics AG and Remitly Global Inc are close in size by market cap, and Remitly Global Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | RELY | |
|---|---|---|
Market Cap | $5.23B | $4.97B |
Sector | Health | Technology |
52-Week High | $76.78 | $25.93 |
52-Week Low | $44.34 | $12.20 |
Enterprise Value | $3.65B | $4.33B |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →